Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzaldehyde SCHEMBL20262882 | 0.85 | POLB (0.50) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL30060739 | 0.84 | TSHR (0.49) | L3MBTL1POLBALDH1A1TP53MAPT | |
| SCHEMBL1665229 | 0.82 | DAO (0.58) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL20262898 | 0.82 | KMT2A (0.40) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL16619843 | 0.81 | KMT2A (0.51) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL20262849 | 0.81 | KMT2A (0.39) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| Dihydrocinnamaldehyde SCHEMBL20262899 | 0.81 | POLB (0.47) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL20262906 | 0.81 | KMT2A (0.41) | KMT2ANPSR1L3MBTL1POLBMEN1 | |
| SCHEMBL20262892 | 0.81 | KMT2A (0.39) | KMT2ANPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL1007015 | 0.81 | MAPK1 (0.61) | KMT2ANPSR1L3MBTL1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4430042-B1 | 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4658655-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | Verge Analytics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4633734-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | Wavebreak Therapeutics, LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-06-24 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006127595-A1 | 5-AMINOPYRAZOLE CARBOXYLIC ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2006-05-04 | — | — | US | disclosed |
| CN-1671710-A | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS INC (US) | 2005-09-21 | — | — | CN | disclosed |
| EP-1511751-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | Neogenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003101993-A1 | PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | KMT2A 4381/4885NPSR1 2933/4885L3MBTL1 3617/4885 |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KMT2A 227/4885NPSR1 475/4885L3MBTL1 4462/4885 |
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | PIKFYVE, PIP4K2B, PIP4K2C | KMT2A 2247/4885NPSR1 4180/4885L3MBTL1 2992/4885 |
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKK, DGKA | KMT2A 2337/4885NPSR1 4320/4885L3MBTL1 4185/4885 |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | KMT2A 2226/4885NPSR1 4206/4885L3MBTL1 1993/4885 |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | KMT2A 3782/4885NPSR1 3710/4885L3MBTL1 4177/4885 |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CDKN1A, EIF2AK2, DCK | KMT2A 1238/4885NPSR1 4657/4885L3MBTL1 2317/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | KMT2A 4487/4885NPSR1 3984/4885L3MBTL1 2102/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | KMT2A 4381/4885NPSR1 2933/4885L3MBTL1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.